MX2015017011A - Compuestos nuevos para el tratamiento del cancer. - Google Patents
Compuestos nuevos para el tratamiento del cancer.Info
- Publication number
- MX2015017011A MX2015017011A MX2015017011A MX2015017011A MX2015017011A MX 2015017011 A MX2015017011 A MX 2015017011A MX 2015017011 A MX2015017011 A MX 2015017011A MX 2015017011 A MX2015017011 A MX 2015017011A MX 2015017011 A MX2015017011 A MX 2015017011A
- Authority
- MX
- Mexico
- Prior art keywords
- compounds
- treatment
- cancer
- novel compounds
- novel
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/428—Thiazoles condensed with carbocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
- C07D277/62—Benzothiazoles
- C07D277/68—Benzothiazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
- C07D277/82—Nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Oncology (AREA)
- Immunology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Thiazole And Isothizaole Compounds (AREA)
Abstract
Compuestos nuevos con efecto inhibidor de la Mps-1 quinasa, métodos para su preparación, composiciones y combinaciones farmacéuticas que comprenden a dichos compuestos, el uso de los compuestos en la elaboración de una composición farmacéutica para el tratamiento o la profilaxis de una enfermedad, así como compuestos intermediarios de utilidad en la preparación de dicho compuestos.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP13171171 | 2013-06-10 | ||
EP13198899 | 2013-12-20 | ||
PCT/EP2014/061530 WO2014198594A1 (en) | 2013-06-10 | 2014-06-04 | Novel compounds for the treatment of cancer |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2015017011A true MX2015017011A (es) | 2016-04-25 |
Family
ID=50897594
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2015017011A MX2015017011A (es) | 2013-06-10 | 2014-06-04 | Compuestos nuevos para el tratamiento del cancer. |
Country Status (25)
Country | Link |
---|---|
US (1) | US20160207928A1 (es) |
EP (1) | EP3008061A1 (es) |
JP (1) | JP2016521737A (es) |
KR (1) | KR20160019426A (es) |
CN (1) | CN105246891A (es) |
AU (1) | AU2014280395A1 (es) |
BR (1) | BR112015030774A2 (es) |
CA (1) | CA2914668A1 (es) |
CL (1) | CL2015003584A1 (es) |
CR (1) | CR20150653A (es) |
CU (1) | CU20150175A7 (es) |
DO (1) | DOP2015000298A (es) |
EA (1) | EA201501175A1 (es) |
HK (1) | HK1219737A1 (es) |
IL (1) | IL242546A0 (es) |
MX (1) | MX2015017011A (es) |
NI (1) | NI201500175A (es) |
PE (1) | PE20160747A1 (es) |
PH (1) | PH12015502747A1 (es) |
SG (1) | SG11201509351UA (es) |
SV (1) | SV2015005126A (es) |
TN (1) | TN2015000542A1 (es) |
TW (1) | TW201529560A (es) |
UY (1) | UY35602A (es) |
WO (1) | WO2014198594A1 (es) |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AP2015008898A0 (en) * | 2013-06-11 | 2015-12-31 | Bayer Pharma AG | Prodrug derivatives of substituted triazolopyridines |
US10913738B2 (en) | 2017-02-13 | 2021-02-09 | Bristol-Myers Squibb Company | Aminotriazolopyridines as kinase inhibitors |
KR102662197B1 (ko) | 2017-10-30 | 2024-04-29 | 브리스톨-마이어스 스큅 컴퍼니 | 키나제 억제제로서의 아미노이미다조피리다진 |
CN109045036B (zh) * | 2018-07-19 | 2020-10-02 | 中山大学 | [1,2,4]三唑并[4,3-b]哒嗪衍生物在制备抗肿瘤药物中的应用 |
CN111393405B (zh) * | 2019-01-02 | 2022-11-25 | 中国科学院上海药物研究所 | 一类含氟取代的苯并噻吩类化合物及其药物组合物及应用 |
US11976052B2 (en) | 2019-01-11 | 2024-05-07 | Naegis Pharmaceuticals Inc. | Leukotriene synthesis inhibitors |
AR123793A1 (es) | 2020-10-19 | 2023-01-11 | Bristol Myers Squibb Co | Compuestos de triazolopiridinilo como inhibidores de quinasas |
Family Cites Families (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2444403A1 (en) * | 2008-04-18 | 2012-04-25 | Shionogi Co., Ltd. | Heterocyclic compound having inhibitory activity on PI3K |
AR071523A1 (es) * | 2008-04-30 | 2010-06-23 | Merck Serono Sa | Compuestos biciclicos fusionados, un proceso para su preparacion, el compuesto para ser utilizado como medicamento en el tratamiento y profilaxis de enfermedades, una composicion farmaceutica y un conjunto que comprende paquetes separados del compuesto y de un ingrediente activo del medicamento |
WO2010007100A1 (en) * | 2008-07-15 | 2010-01-21 | Cellzome Ltd | 7-substituted amino triazoles as pi3k inhibitors |
US8420052B2 (en) * | 2008-07-24 | 2013-04-16 | Siemens Medical Solutions Usa, Inc. | Imaging agents useful for identifying AD pathology |
TWI453207B (zh) * | 2008-09-08 | 2014-09-21 | Signal Pharm Llc | 胺基三唑并吡啶,其組合物及使用其之治療方法 |
WO2011110575A1 (en) * | 2010-03-11 | 2011-09-15 | Glaxo Group Limited | Derivatives of 2-[2-(benzo- or pyrido-) thiazolylamino]-6-aminopyridine, useful in the treatment of respiratoric, allergic or inflammatory diseases |
TW201204723A (en) * | 2010-06-22 | 2012-02-01 | Fovea Pharmaceuticals | Heterocyclic compounds, their preparation and their therapeutic application |
EP2651950A1 (en) * | 2010-12-17 | 2013-10-23 | Bayer Intellectual Property GmbH | 6 substituted imidazopyrazines for use as mps-1 and tkk inhibitors in the treatment of hyperproliferative disorders |
ES2545135T3 (es) * | 2011-04-06 | 2015-09-08 | Bayer Pharma Aktiengesellschaft | Imidazopiridinas sustituidas y compuestos intermedios de las mismas |
PT2699575E (pt) * | 2011-04-21 | 2015-07-29 | Bayer Ip Gmbh | Triazolopiridinas |
WO2012160029A1 (en) * | 2011-05-23 | 2012-11-29 | Bayer Intellectual Property Gmbh | Substituted triazolopyridines |
AU2013230286B2 (en) * | 2012-03-07 | 2016-12-22 | Merck Patent Gmbh | Triazolopyrazine derivatives |
-
2014
- 2014-06-04 CA CA2914668A patent/CA2914668A1/en not_active Abandoned
- 2014-06-04 MX MX2015017011A patent/MX2015017011A/es unknown
- 2014-06-04 SG SG11201509351UA patent/SG11201509351UA/en unknown
- 2014-06-04 TN TN2015000542A patent/TN2015000542A1/en unknown
- 2014-06-04 EA EA201501175A patent/EA201501175A1/ru unknown
- 2014-06-04 PE PE2015002596A patent/PE20160747A1/es not_active Application Discontinuation
- 2014-06-04 WO PCT/EP2014/061530 patent/WO2014198594A1/en active Application Filing
- 2014-06-04 JP JP2016518921A patent/JP2016521737A/ja active Pending
- 2014-06-04 EP EP14728921.9A patent/EP3008061A1/en not_active Withdrawn
- 2014-06-04 KR KR1020157034736A patent/KR20160019426A/ko not_active Application Discontinuation
- 2014-06-04 US US14/896,450 patent/US20160207928A1/en not_active Abandoned
- 2014-06-04 CN CN201480032697.9A patent/CN105246891A/zh active Pending
- 2014-06-04 BR BR112015030774A patent/BR112015030774A2/pt not_active IP Right Cessation
- 2014-06-04 AU AU2014280395A patent/AU2014280395A1/en not_active Abandoned
- 2014-06-10 TW TW103120105A patent/TW201529560A/zh unknown
- 2014-06-10 UY UY0001035602A patent/UY35602A/es not_active Application Discontinuation
-
2015
- 2015-11-11 IL IL242546A patent/IL242546A0/en unknown
- 2015-12-09 PH PH12015502747A patent/PH12015502747A1/en unknown
- 2015-12-10 CR CR20150653A patent/CR20150653A/es unknown
- 2015-12-10 NI NI201500175A patent/NI201500175A/es unknown
- 2015-12-10 CU CUP2015000175A patent/CU20150175A7/es unknown
- 2015-12-10 DO DO2015000298A patent/DOP2015000298A/es unknown
- 2015-12-10 CL CL2015003584A patent/CL2015003584A1/es unknown
- 2015-12-10 SV SV2015005126A patent/SV2015005126A/es unknown
-
2016
- 2016-07-06 HK HK16107837.4A patent/HK1219737A1/zh unknown
Also Published As
Publication number | Publication date |
---|---|
DOP2015000298A (es) | 2016-03-15 |
HK1219737A1 (zh) | 2017-04-13 |
SV2015005126A (es) | 2017-01-30 |
CA2914668A1 (en) | 2014-12-18 |
CR20150653A (es) | 2016-03-04 |
CU20150175A7 (es) | 2016-05-30 |
PE20160747A1 (es) | 2016-08-25 |
US20160207928A1 (en) | 2016-07-21 |
SG11201509351UA (en) | 2015-12-30 |
NI201500175A (es) | 2016-01-06 |
PH12015502747A1 (en) | 2016-03-14 |
KR20160019426A (ko) | 2016-02-19 |
BR112015030774A2 (pt) | 2017-07-25 |
WO2014198594A1 (en) | 2014-12-18 |
TN2015000542A1 (en) | 2017-04-06 |
UY35602A (es) | 2015-01-30 |
TW201529560A (zh) | 2015-08-01 |
AU2014280395A1 (en) | 2015-12-17 |
IL242546A0 (en) | 2016-02-01 |
CN105246891A (zh) | 2016-01-13 |
EA201501175A1 (ru) | 2016-10-31 |
CL2015003584A1 (es) | 2016-06-24 |
JP2016521737A (ja) | 2016-07-25 |
EP3008061A1 (en) | 2016-04-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2016013689A (es) | Compuestos 4-amino-imidazoquinolina. | |
MX2016016666A (es) | Derivados de acido boronico y usos terapeuticos de los mismos. | |
MX2016002544A (es) | Compuestos utiles como inmunomoduladores. | |
MX2016015093A (es) | Derivados de acido boronico y sus usos terapeuticos. | |
PH12015502747A1 (en) | Novel compounds for the treatment of cancer | |
MX364486B (es) | Derivados de piridazinona-amidas. | |
GB201209613D0 (en) | New compounds | |
MX2015008627A (es) | Derivados de acido boronico y usos terapeuticos de los mismos. | |
MX2015008628A (es) | Derivados de acido boronico y usos terapeuticos de los mismos. | |
MX2016016143A (es) | Compuestos de [1,2,4]triazol sustituido. | |
MX2015012414A (es) | Sal de omecamtiv mecarbilo y proceso para preparar la sal. | |
PH12016501807A1 (en) | Novel compounds | |
PH12017501133A1 (en) | Pyrazolopyridinamines | |
CA2929436C (en) | Compounds, pharmaceutical composition and methods for use in treating inflammatory diseases | |
PH12016501814A1 (en) | Inhibitors of the wnt signalling pathways | |
MX366829B (es) | Composiciones y formas de dosificacion de itraconazol y metodos de uso de las mismas. | |
PH12017501122A1 (en) | Substituted pyridyl-cycloalkyl-carboxylic acids, compositions containing them and medical uses thereof | |
PH12015502746A1 (en) | Prodrug derivatives of substituted triazolopyridines | |
EP2983684B8 (en) | Essential oil and aloe for treatment and prophylaxis of inflammations caused by demodex, especially marginal blepharitis, a pharmaceutical composition containing essential oil and/or aloe and the use of essential oil and aloe and their compositions for the production of a preparation used in treatment and prophylaxis of the mentioned inflammations | |
WO2015044961A3 (en) | Pharmaceutical composition comprising capecitabine and cyclophosphamide | |
EA201591449A1 (ru) | Способы получения противораковых композиций | |
PH12015502703A1 (en) | Pharmaceutical compositions | |
MA39762A (fr) | Nouveaux composés | |
IN2013CH05858A (es) |